Tactile Systems Technology ( (TCMD) ) has released its Q1 earnings. Here is a breakdown of the information Tactile Systems Technology presented to its investors.
Tactile Systems Technology, Inc., operating as Tactile Medical, is a medical technology company that develops and markets at-home therapies for chronic conditions such as lymphedema and chronic pulmonary disease, focusing on improving patients’ quality of life and reducing healthcare costs.
In its first quarter of 2025, Tactile Medical reported a slight revenue increase of 0.3% year-over-year to $61.3 million, with a gross margin improvement to 74%. Despite these gains, the company experienced a net loss of $3.0 million, compared to a $2.2 million net loss in the same period last year.
Key financial metrics showed mixed results, with a notable increase in gross profit by 4% due to reduced manufacturing costs, while operating expenses rose by 8% due to strategic investments. The company also repurchased $10 million of its stock and expanded its product offerings, including the launch of Nimbl for lower extremity lymphedema.
Looking ahead, Tactile Medical has adjusted its 2025 financial outlook, now expecting total revenue growth of 5% to 8% year-over-year, slightly down from previous estimates. The company remains focused on strategic priorities to maintain its leadership in the lymphatic therapy market.